Wells Fargo upgraded Integra LifeSciences to Overweight from Equal Weight with a price target of $49, up from $40. The analyst now has increased confidence in the company’s ability to restart commercial distribution from its Boston facility by mid-to-late Q2 of 2024. The restart of the facility represents an inflection point for the shares, the analyst tells investors in a research note. The firm says that as commercial distribution resumes, Integra’s margins should expand and earnings will improve.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IART:
- Kraft Heinz upgraded, AMD initiated: Wall Street’s top analyst calls
- Integra LifeSciences initiated with a Buy at CL King
- Integra LifeSciences price target lowered to $39 from $41 at Truist
- Integra LifeSciences price target lowered to $40 from $47 at Wells Fargo
- Integra LifeSciences sees Q4 adjusted EPS 89c-93c, consensus 92c